Sasaki, K., Kantarjian, H., Jabbour, E., Ravandi, F., Takahashi, K., Konopleva, M., Borthakur, G., Garcia-Manero, G., Wierda, W., Daver, N., Jain, P., Satta, T., Pierce, S., Rios, M. B. and Cortes, J. E. (2016) “Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis”, Haematologica. Pavia, Italy, 101(8), pp. e324-e327. doi: 10.3324/haematol.2015.139089.